Analysis of the impact of lung cancer treatment on nontuberculous mycobacterial lung diseases

Tsuji, Taisuke; Tsuyuguchi, Kazunari; Tachibana, Kazunobu; Kimura, Yuri; Kobayashi, Takehiko; Minomo, Shojiro; Atagi, Shinji; Matsumura, Akira; Hayashi, Seiji; Suzuki, Katsuhiro

doi:10.1016/j.resinv.2016.08.002

Cited by 15 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the previous reports regarding the complication of lung cancer and pulmonary MAC disease described clinical characteristics of patients diagnosed with pulmonary MAC disease before lung cancer or diagnosed simultaneously with pulmonary MAC disease and lung cancer [10] [17] [18] [19]. To our knowledge, there are a few reports about the clinical characteristics of patients diagnosed with pulmonary MAC disease after lung cancer [17] [20] [21].…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Mycobacterium avium Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Kobashi¹,

Abe²,

Yoshioka³

et al. 2019

JTR

View full text Add to dashboard Cite

Case 1 was a 49-year-old woman who visited with a dry cough. She had an underlying disease of lung adenocarcinoma and received cancer immunotherapy because of an ALK-positive response and several cancer chemotherapies. The clinical effect was a complete response. Chest CT was performed because of continuous dry cough, and a new tumor shadow was recognized in the lingula portion of the left upper lobe. We performed CT-guided lung biopsy and could aspirate pus-fluid. The culture test for acid-fast bacilli was positive and the causative microorganism was identified as Mycobacterium avium by the DDH method. The final diagnosis was pulmonary abscess due to M. avium. Treatment using combined chemotherapy including CAM was performed and a good clinical response was obtained. Case 2 was a 67-year-old man who had a past history of surgical resection of lung adenocarcinoma eight and two years ago and received several cancer chemotherapies and radiation therapy. Because a new nodular shadow appeared in the right middle lobe one year ago and showed strong positivity on PET/CT, surgical resection was performed with the suspected recurrence of lung cancer. Subsequently, the histological diagnosis was epithelioid granuloma and a culture test of acid-fast bacilli was positive, with the identification of Mycobacterium intracellulare by the DDH method. Combined chemotherapy was not performed because the lesion was completely resected. Afterwards, a new nodular shadow appeared in the left lower lobe again and bronchoscopy was performed. Because M. intracellulare was isolated from the local specimen, we diagnosed the patient with recurrence of pulmonary MAC disease and combined chemotherapy including CAM was performed for one year. Finally, the nodular lesion disappeared.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary Mycobacterium avium Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Kobashi¹,

Abe²,

Yoshioka³

et al. 2019

JTR

View full text Add to dashboard Cite

show abstract

“…SCLC with MAC infection is rare. The incidence of MAC infection among male and female patients with lung cancer is 8.6 and 6.3%, respectively [7], and the incidence of SCLC among those with lung cancer with MAC infection is 6.9% [8]. …”

Section: Discussion/conclusionmentioning

confidence: 99%

“…Lung cancer often concurrently exists with pulmonary MAC infection [7, 8]. The most frequent histological type of lung cancer coexisting with MAC is adenocarcinoma, and SCLC is relatively rare.…”

Section: Introductionmentioning

confidence: 99%

Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report

et al. 2018

View full text Add to dashboard Cite

Background: Small-cell lung cancer (SCLC) rarely coexists with pulmonary Mycobacterium avium intracellular complex (MAC) infection. The key drug for SCLC treatment is etoposide, which is metabolized by cytochrome P-450 (CYP) 3A4. Meanwhile, the key drugs for pulmonary MAC infection are clarithromycin (CAM) and rifampicin (RFP), and their metabolism influences CYP3A4. Therefore, treatment of concurrent SCLC and pulmonary MAC infection is difficult, and to the best of our knowledge, no report of treatments for concurrent SCLC and pulmonary MAC infection has been published. Patient Concerns and Diagnoses: A 65-year-old man presented to our hospital with abnormal findings of chest computed tomography: (1) a hilar region nodule in the left lung and mediastinal lymphadenopathy and (2) a thick-walled cavity lesion in the right upper lobe of the lung. After further examinations, the former lesions were diagnosed as SCLC, cT4N3M0, stage IIIC and the latter as pulmonary MAC infection, fibrocavitary disease. Interventions and Outcomes: Concurrent treatment was conducted with discontinuation of CAM and RFP before and after etoposide administration. Specifically, intravenous cisplatin and etoposide were administered on day 1 and days 1–3, respectively, and CAM, RFP, and ethambutol (EB) were administered orally on days 6–22 every 4 weeks. Concurrent radiotherapy was added to the drug administration on days 1–27 of the first cycle. The chemotherapy was continued for 4 cycles, followed by continuation of CAM and RFP administration. EB was discontinued because of optic nerve disorder. The treatments were conducted completely and safely, and both of the SCLC lesions and the MAC lesion were improved. Conclusions: Treatments for concurrent SCLC and pulmonary MAC infection may be successfully conducted with discontinuation of CAM and RFP before and after etoposide administration.

show abstract

“…There is a possibility of co-existing pulmonary NTM infection in patients with lung cancer and disseminated NTM infection in patients with hematologic cancer [88,89]. A study has suggested that anti-NTM therapy should be introduced only with worsening of symptoms under careful consideration as anti-NTM treatment is long and anti-mycobacterial drugs have extensive effects on anti-cancer drugs [90].…”

Section: Mycobacterium -Research and Developmentmentioning

confidence: 99%

Overview of Non Tuberculosis Mycobacterial Lung Diseases

Diseases¹

2018

Mycobacterium - Research and Development

View full text Add to dashboard Cite

Nontuberculosis mycobacteria (NTM) are ubiquitous in nature and opportunistically infect different animals, including humans. Currently, NTM is emerging as an important cause of pulmonary infection among both immunocompromised and immunocompetent persons worldwide. The clinical relevance of pulmonary NTM varies among species while showing geographical heterogeneity in distribution as well as pathogenicity. The outcome of the respiratory NTM disease is a consequence of a complex interplay between microbial factors and host susceptibility. Furthermore, HIV infection, cystic fibrosis, cancer, underlying chronic lung disease and history of tuberculosis (TB) may be associated as risk factors for active nontuberculosis pulmonary diseases (NTMPD). The diagnosis of NTMPD requires the presence of symptoms, radiographic evidences, microscopic observations and definitive laboratory diagnostics. Lung infections resulted from a clinically significant NTM species should be treated with appropriate antimicrobial regimen. M. leprae and M. lepraemurium are uncultivable and require the intracellular milieu for survival and propagation [4]. The obligatory causative agents of the genus Mycobacterium, responsible for TB are classified into Mycobacterium tuberculosis complex (MTC). It comprises M. tuberculosis, M.bovis, M. africanum, M. microti [5], M. canettii [6], M. caprae [7], M. pinnipedii [8], M. mungi [9], M. orygis [10] and M. suricattae [11] species. M. tuberculosis, M. africanum, M. canettii and M. orygis cause TB primarily in human [4, 10], whereas M. bovis [12], M. microti [13], M. caprae [7] M. pinnipedii [8], M. mungi [9] and M. suricattae [11] infect cattle, domestic animals, goats, seals, mongooses and meerkats, respectively, and animal tuberculosis can also be zoonotic [14, 15]. However, geographical variation of the MTC species distribution has been identified. As an example, M. africanum is a common cause of human pulmonary TB (39%) as much as M. tuberculosis (55%) in West Africa [16]. In Ghana, 3% of pulmonary TB cases are represented by M. bovis, while 20% are M. africanum and 73% are M. tuberculosis [17].Other medically important mycobacteria such as M. avium, M. intracellulare complex, M. kansasii, M. marinum, M. fortuitum, M. chelonae complex, M. abscessus and M. scrofulaceum are known as nontuberculosis mycobacteria (NTM) species or atypical mycobacteria or mycobacteria other than tuberculosis (MOTT). They are responsible for diseases including lymphadenitis in children, chronic pulmonary diseases, skin and soft-tissue diseases and infections of the skeletal system [18]. NTM are ubiquitous in nature and are widely distributed in water, soil and animals. Among prevailing NTM species, only a few species have a clinical impact on humans as opportunistic pathogens [19]. M. avium complex (MAC), M. abscessus, M. kansasii, M. fortuitum, M. chelonae, M. szulgai, M. triviale and M. scrofulaceum are common NTM species that cause pulmonary diseases in human [20]. Additionally, M. riyadhense was recently proposed as a cau...

show abstract

Analysis of the impact of lung cancer treatment on nontuberculous mycobacterial lung diseases

Cited by 15 publications

References 27 publications

Pulmonary <i>Mycobacterium avium </i> Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Pulmonary <i>Mycobacterium avium </i> Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Small-Cell Lung Cancer Comorbid with Pulmonary <b><i>Mycobacterium avium</i></b> Infection: A Case Report

Overview of Non Tuberculosis Mycobacterial Lung Diseases

Contact Info

Product

Resources

About

Analysis of the impact of lung cancer treatment on nontuberculous mycobacterial lung diseases

Cited by 15 publications

References 27 publications

Pulmonary &lt;i&gt;Mycobacterium avium &lt;/i&gt; Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Pulmonary &lt;i&gt;Mycobacterium avium &lt;/i&gt; Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Small-Cell Lung Cancer Comorbid with Pulmonary <b><i>Mycobacterium avium</i></b> Infection: A Case Report

Overview of Non Tuberculosis Mycobacterial Lung Diseases

Contact Info

Product

Resources

About

Pulmonary <i>Mycobacterium avium </i> Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer

Pulmonary <i>Mycobacterium avium </i> Complex Disease Requiring Differentiation from Recurrence of Lung Cancer during the Follow-Up Period for Lung Cancer